Abstract
Systemic lupus erythematosus (SLE) predominantly affects women of childbearing age, and the management of pregnant patients with SLE is challenging because pregnancy can aggravate SLE and vice versa. Furthermore, the drugs used to treat SLE can adversely affect the fetus. Accordin-gly, pregnancy should be planned in advance in women with lupus, and careful planning and treatment are required to care for women with lupus who become pregnant. This article reviews the pre-pregnancy evaluation and management of pregnant women with SLE with the aim of providing general guidelines to physicians regarding the monitoring and treatment of women with SLE that want to become pregnant.
References
1. Harley JB, Kelly JA, Kaufman KM. Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol. 2006; 28:119–30.
2. Boumpas DT, Fessler BJ, Austin HA 3rd, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med. 1995; 123:42–53.
3. Geva E, Lerner-Geva L, Burke M, Vardinon N, Lessing JB, Amit A. Undiagnosed systemic lupus erythematosus in a cohort of infertile women. Am J Reprod Immunol. 2004; 51:336–40.
4. Silva CA, Leal MM, Leone C, Simone VP, Takiuti AD, Saito MI, et al. Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus. 2002; 11:419–25.
6. Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: ten questions and some answers. Lupus. 2008; 17:416–20.
7. Ruiz-Irastorza G, Khamashta MA. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol. 2009; 23:575–82.
8. Giles I, Rahman A. How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. Best Pract Res Clin Rheumatol. 2009; 23:525–37.
9. Costedoat-Chalumeau N, Georgin-Lavialle S, Amoura Z, Piette JC. Anti-SSA/Ro and anti-SSB/La antibody-med-iated congenital heart block. Lupus. 2005; 14:660–4.
10. Khamashta MA. Systemic lupus erythematosus and pregnancy. Best Pract Res Clin Rheumatol. 2006; 20:685–94.
11. Buyon JP, Kalunian KC, Ramsey-Goldman R, Petri MA, Lockshin MD, Ruiz-Irastorza G, et al. Assessing disease activity in SLE patients during pregnancy. Lupus. 1999; 8:677–84.
12. Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006; 8:209.
13. Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J. 2009; 7:9.
14. Witter FR. Management of the high-risk lupus pregnant patient. Rheum Dis Clin North Am. 2007; 33:253–65.
15. Le Thi Thuong D, Tieulié N, Costedoat N, Andreu MR, Wechsler B, Vauthier-Brouzes D, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis. 2005; 64:273–8.
16. Carmona F, Font J, Cervera R, Muñoz F, Cararach V, Balasch J. Obstetrical outcome of pregnancy in patients with systemic Lupus erythematosus. A study of 60 cases. Eur J Obstet Gynecol Reprod Biol. 1999; 83:137–42.
18. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006; 295:1050–7.
19. Tincani A, Branch W, Levy RA, Piette JC, Carp H, Rai RS, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus. 2003; 12:524–9.
21. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007; 369:1791–8.
23. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and re-currence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998; 31:1658–66.
24. Eronen M, Sirèn MK, Ekblad H, Tikanoja T, Julkunen H, Paavilainen T. Short- and longterm outcome of children with congenital complete heart block diagnosed in utero or as a newborn. Pediatrics. 2000; 106:86–91.
25. Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus. 2006; 15:148–55.
Table 1.
Table 2.
Table 3.
NSAIDs: nonsteroidal antiinflammatory drugs, Anti-TNF: antitumor necrosis factor The United States Food and Drug Administration (FDA) pregnancy risk categories are as follows: A: no risk in controlled clinical studies in humans, B: human data reassuring, and when absent, animal studies show no risk, C: human data lacking, but animals studies indicate risk or have not been done, D: positive evidence of risk, but benefit may outweigh the risk, X: contraindicated during pregnancy